A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors


This is a first in human phase I study of single agent CGM097 in patients with advanced solid tumors who have progressed despite standard therapy or for whom no standard therapy exists. The tumor must be characterized by p53wt status. The study consists of a dose escalation part where patients will receive escalating doses of CGM097, and a dose expansion part in which patients are given CGM097 at the maximum tolerated dose (MTD) or Recommended Phase 2 Dose (RP2D). Each dose escalation step will be decided based on the recommendation from an adaptive Bayesian logistic regression model (BLRM).

Study Start Date

March 2013

Estimated Completion Date

June 2016


  • Drug: CGM097


  • Oncology: Pharmacology/Therapy
  • Pharmacy: Chemotherapy/Oncology,Drug Trials

MeSH Terms

  • CGM097
  • Neoplasms
  • Solid Tumor

Study ID

Novartis -- CCGM097X2101



Trial ID


Study Type


Trial Phase

Phase 1

Enrollment Quota




Inclusion Criteria

  • Patient has advanced solid malignancy that has progressed despite standard therapy, or for which no effective standard therapy exists
  • Tumor of the patient is p53wt
  • Evaluable disease as determined by RECIST 1.1
  • WHO performance status 0-2 Exclusion criteria:
  • Prior treatment with CGM097 or other p53/HDM2-interaction inhibitor
  • Patient with symptomatic or growing CNS metastatic lesions
  • Concurrent other malignancy
  • Clinically significant cardiac disease as defined in the protocol
  • Diagnosis of acute or chronic pancreatitis
  • Concomitant therapy that precludes enrollment, as defined in the protocol
  • Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 2 weeks after study drug discontinuation
  • Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may apply.




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Dana Farber Cancer Institute SC 2 - Boston, Massachusetts 2.4 miles Boris Osipov 617-632-6708 bosipovov@partners.org

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.